EcoDrugPlus

Hydroxycarboxylic Acid Receptor 2

Ensembl ID : ENSDLEG00000009885
Gene Symbol: HCAR2
3 Cross references
163 Possible Orthologues:

Hydroxysteroid 11-Beta Dehydrogenase 1

Ensembl ID : ENSDLEG00000005534
Gene Symbol: HSD11B1
3 Cross references
267 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSDLEG00000002750
Gene Symbol: HCN4
3 Cross references
288 Possible Orthologues:

Hypocretin Receptor 1

Ensembl ID : ENSDLEG00000015922
Gene Symbol: HCRTR1
3 Cross references
95 Possible Orthologues:

Hypocretin Receptor 2

Ensembl ID : ENSDLEG00000021982
Gene Symbol: HCRTR2
3 Cross references
199 Possible Orthologues:

Indoleamine 2,3-Dioxygenase 1

Ensembl ID : ENSDLEG00000007248
Gene Symbol: IDO1
1 Cross references
98 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSDLEG00000021376
Gene Symbol: IKBKB
3 Cross references
197 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 1

Ensembl ID : ENSDLEG00000012587
Gene Symbol: IMPDH1
2 Cross references
330 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 2

Ensembl ID : ENSDLEG00000018135
Gene Symbol: IMPDH2
1 Cross references
201 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSDLEG00000010154
Gene Symbol: INPP5D
1 Cross references
214 Possible Orthologues:

Insulin Like Growth Factor 1 Receptor

Ensembl ID : ENSDLEG00000006865
Gene Symbol: IGF1R
3 Cross references
276 Possible Orthologues:

Integrin Subunit Alpha 2b

Ensembl ID : ENSDLEG00000007305
Gene Symbol: ITGA2B
1 Cross references
191 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).